Parents of a transgender teenage boy have asked an Ohio family court to stop their child from receiving hormone therapy, reports CNN.
The 17-year-old boy, whose name has been kept anonymous, took his parents to court in order to be able to receive treatment for gender dysphoria at Cincinnati Children’s Hospital Medical Center. The teen suffers from anxiety and depression related to his gender dysphoria, and began experiencing suicidal ideation after his parents refused to acknowledge his gender identity.
The boy has been living with his maternal grandparents while the court battle rages on. But the teens’ parents have asked that the child continue living with his grandparents, even if the court decides that the parents are the ones who should make choices about whether the teen pursues his transition.
Karen Brinkman, an attorney representing the parents, says that it is in the teen’s best interest to continue living with his grandparents, though the parents are best suited to retain custody and make medical decisions for their child.
Brinkman maintains that the teen’s current mental state hinders him from making an informed decision about his health care.
“It does not appear that this child is even close to being able to make such a life-altering decision at this time,” she said.
The grandparents have previously told the court that they are willing to allow their grandchild to receive treatment for gender dysphoria, including hormone therapy, if it is deemed medically necessary.
In 2016, the teen was hospitalized and treated for gender dysphoria. But his parents put a stop to the therapy, citing religious objections and a desire to seek out a Christian therapist to help their child deal with his feelings.
In November 2016, the teen told a local crisis hotline that his father had told him to kill himself. The teen also claims that his parents made him sit in a room and listen to Bible scripture for over six hours in an effort to purge him of his feelings of gender dysphoria. A month later, the teen claims he tried to read a letter to his parents explaining his feelings, but his mother screamed at him and called him a liar. Eventually, the parents relented and allowed him to resume counseling-type therapy to deal with his suicidal ideation.
The boys’ medical providers at Cincinnati Children’s say that the boy has improved mentally and emotionally from his therapy, and that the grandparents have created a supportive environment. But the medical team believes that starting hormone therapy and other treatments will help the teen transition more smoothly.
A New York City subway rider was slashed in the face earlier this month by an unidentified assailant who took offense to him kissing his transgender partner. The attack occurred around 7:50 p.m. on January 10 aboard a southbound No. 6 train as it traveled through Manhattan.
According to police, the 28-year-old victim was kissing his partner when the suspect began shouting anti-gay slurs. The verbal abuse quickly escalated into a physical confrontation. During the argument, the suspect struck the victim with a sharp object, causing a deep laceration on the right side of his face, according to New York CW affiliate WPIX.
In late November, the University of Oklahoma placed Mel Curth on administrative leave after the transgender graduate teaching assistant gave a student a zero on an essay about gender roles.
The essay cited the Bible to defend traditional gender roles and described transgender people as "demonic." Curth and the course's instructor, Megan Waldron, said the paper failed to meet basic academic standards due to a lack of empirical evidence. Both noted that the paper cited no scholarly sources and failed to offer an evidence-based critique of the assigned article, which argued that children who do not conform to rigid gender stereotypes are more likely to face bullying and negative mental health outcomes.
A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir -- marketed as Yeztugo by Gilead Sciences -- do not have clinically significant interactions with gender-affirming hormone therapy.
"In the most gender-diverse Phase III PrEP trial conducted to date, lenacapavir had no clinically significant impact on feminizing or masculinizing gender-affirming therapy concentrations," the study’s researchers concluded, as reported by POZ.
The study, led by Dr. Jill Blumenthal of the University of California San Diego, examined whether lenacapavir interacts with gender-affirming hormone therapy, including estradiol (a form of estrogen) and testosterone. Because those hormones are metabolized by enzymes such as CYP3A4 -- which lenacapavir can inhibit -- the researchers analyzed whether the drug altered hormone levels.
These are challenging times for news organizations. And yet it’s crucial we stay active and provide vital resources and information to both our local readers and the world. So won’t you please take a moment and consider supporting Metro Weekly with a membership? For as little as $5 a month, you can help ensure Metro Weekly magazine and MetroWeekly.com remain free, viable resources as we provide the best, most diverse, culturally-resonant LGBTQ coverage in both the D.C. region and around the world. Memberships come with exclusive perks and discounts, your own personal digital delivery of each week’s magazine (and an archive), access to our Member's Lounge when it launches this fall, and exclusive members-only items like Metro Weekly Membership Mugs and Tote Bags! Check out all our membership levels here and please join us today!
You must be logged in to post a comment.